Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT02946996 Active, not recruiting - Prostate Cancer Clinical Trials

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Start date: December 28, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at the effect that the study drug OPC has on AGE levels in patients with prostate cancer.

NCT ID: NCT02925702 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

PRORADIUM
Start date: February 2016
Phase:
Study type: Observational

PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.

NCT ID: NCT02923180 Active, not recruiting - Prostate Cancer Clinical Trials

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Start date: February 14, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical prostatectomy.

NCT ID: NCT02922218 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

PROSENZA
Start date: June 2016
Phase:
Study type: Observational

PROSENZA is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with enzalutamide

NCT ID: NCT02920229 Active, not recruiting - Prostate Cancer Clinical Trials

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

GaPSMA
Start date: November 2015
Phase: N/A
Study type: Interventional

Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-[fluorine-18] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan.

NCT ID: NCT02913196 Active, not recruiting - Clinical trials for Prostate Cancer Metastatic

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Start date: December 30, 2016
Phase: Phase 1
Study type: Interventional

This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate, docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer (mCRPC). This study is designed to determine the dose that apalutamide can be administered safely in combination with abiraterone acetate, docetaxel and prednisone.

NCT ID: NCT02911636 Active, not recruiting - Prostate Cancer Clinical Trials

5 Fractions of Pelvic SABR With Intra Prostatic SABR

5STAR
Start date: October 2016
Phase: N/A
Study type: Interventional

Stereotactic Ablative Radiation(SABR) 35 Gy in 5 fractions, once weekly to prostate with simultaneous intraprostatic boost to the MR detected nodule up to 50Gy + 25 Gy in 5 fractions, once weekly simultaneously to seminal vesicles (SV's) and pelvic lymph nodes + 6-18 months of ADT

NCT ID: NCT02905318 Active, not recruiting - Prostate Cancer Clinical Trials

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: July 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

NCT ID: NCT02903368 Active, not recruiting - Prostate Cancer Clinical Trials

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Start date: October 19, 2016
Phase: Phase 2
Study type: Interventional

This multicenter randomized phase II trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).

NCT ID: NCT02895854 Active, not recruiting - Prostate Cancer Clinical Trials

LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients

BRAVEROBO
Start date: January 8, 2013
Phase: N/A
Study type: Interventional

The aim of this trial is to find out if there are any differences in the profiles of acute and late adverse effects among men with low and intermediate risk prostate cancer treated either with low dose-rate brachytherapy or hypofractionated external radiotherapy (CyberKnife). Also the prostate specific antigen (PSA) responses and cost utility of each treatment will be analysed.